EGFR-TKIs have become first-line therapy drugs for patients with NSCLC harboring EGFR-Mut cells; the majority of patients with an initial response to Gef will develop resistance due to the effects of drug-resistant mutations through T790M mutations or other compensatory activation mechanisms [42,43,44]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.